Antimicrobial Therapy in Patients With Escherichia coli O157:H7 Infection

Abstract
Shiga toxin–producing Escherichia coli O157:H7 is an important cause of enteric illness in developed countries.1 Infection typically presents as a diarrheal illness, often with bloody stools. In approximately 8% of patients,2 infection progresses to hemolytic uremic syndrome (HUS), a life-threatening condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal failure.

This publication has 13 references indexed in Scilit: